Genetics may be more responsible for an association between psychedelic use by teens and manic symptoms than the use of the drug itself. A recent study of 16,255 adolescent twins found that psychedelic use was associated with lower rates of psychotic symptoms when adjusting for other drug use. However, psychedelic use was associated with more manic symptoms in teens with a higher genetic vulnerability to schizophrenia or bipolar I disorder. The findings are focused on psychedelic-assisted therapy, which has shown promise in treating some psychiatric disorders. However, little is known about the risk of psychotic or manic symptoms in teens who use psychedelics recreationally, not therapeutically. This study used the Swedish Twin Registry to investigate links between recreational psychedelic use and self-reported psychotic or manic symptoms in adolescents. Among the 16,255 participants included in the analyses, 541 reported past use of psychedelics, most of whom (535 of 541 [99%]) also reported past use of other drugs. The findings come with significant limitations and should be interpreted with caution, the researchers concluded. Among the conflicts of interest reported, the lead author was the founder of Eudelics, a company which markets mindfulness, leadership, and psychedelics. Simonsson, O., et al. (2024, Mar 13). Adolescent psychedelic use and psychotic or manic symptoms. JAMA Psychiatry. Published online. https://doi.org/10.1001/jamapsychiatry.2024.0047.
青少年使用迷幻药与躁狂症状之间的联系，遗传因素可能比使用迷幻药本身更重要。最近对16255对青少年双胞胎进行的一项研究发现，在对使用其他药物的情况进行调整后，使用迷幻药与较低的精神病症状发生率有关。然而，在精神分裂症或双相情感障碍遗传易感性较高的青少年中，使用迷幻药与更多的躁狂症状有关。研究结果主要针对迷幻药辅助疗法，该疗法在治疗某些精神疾病方面已显示出前景。然而，人们对娱乐性而非治疗性使用迷幻药的青少年出现精神病或躁狂症状的风险知之甚少。这项研究利用瑞典双胞胎登记处调查了青少年娱乐性使用迷幻药与自我报告的精神病或狂躁症状之间的联系。在纳入分析的16255名参与者中，有541人报告过去曾使用过迷幻药，其中大多数人（541人中的535人[99%]）还报告过去曾使用过其他药物。研究人员总结说，这些研究结果有很大的局限性，应谨慎解读。在报告的利益冲突中，主要作者是Eudelics公司的创始人，该公司主要销售正念、领导力和迷幻药。Simonsson, O. 等人（2024年3月13日）。青少年使用迷幻药与精神病或躁狂症状》。美国医学会杂志精神病学》。https://doi.org/10.1001/jamapsychiatry.2024.0047.
{"title":"Researchers consider links between genetics and psychosis in teen use of psychedelics","authors":"Alison Knopf","doi":"10.1002/cpu30860","DOIUrl":"https://doi.org/10.1002/cpu30860","url":null,"abstract":"<p>Genetics may be more responsible for an association between psychedelic use by teens and manic symptoms than the use of the drug itself. A recent study of 16,255 adolescent twins found that psychedelic use was associated with lower rates of psychotic symptoms when adjusting for other drug use. However, psychedelic use was associated with more manic symptoms in teens with a higher genetic vulnerability to schizophrenia or bipolar I disorder. The findings are focused on psychedelic-assisted therapy, which has shown promise in treating some psychiatric disorders. However, little is known about the risk of psychotic or manic symptoms in teens who use psychedelics recreationally, not therapeutically. This study used the Swedish Twin Registry to investigate links between recreational psychedelic use and self-reported psychotic or manic symptoms in adolescents. Among the 16,255 participants included in the analyses, 541 reported past use of psychedelics, most of whom (535 of 541 [99%]) also reported past use of other drugs. The findings come with significant limitations and should be interpreted with caution, the researchers concluded. Among the conflicts of interest reported, the lead author was the founder of Eudelics, a company which markets mindfulness, leadership, and psychedelics. Simonsson, O., et al. (2024, Mar 13). Adolescent psychedelic use and psychotic or manic symptoms. <i>JAMA Psychiatry</i>. Published online. https://doi.org/10.1001/jamapsychiatry.2024.0047.</p>","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140552075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Required activities for federal Pregnant and Postpartum Women residential services program","authors":"Alison Knopf","doi":"10.1002/cpu30864","DOIUrl":"https://doi.org/10.1002/cpu30864","url":null,"abstract":"","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140552079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"FDA warning on delta-8","authors":"","doi":"10.1002/cpu30865","DOIUrl":"https://doi.org/10.1002/cpu30865","url":null,"abstract":"<p>Here are five things you should know about delta-8 THC to keep you and those you care for safe from products that may pose serious health risks.</p>","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140552080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Lithium for BD and CD: The little data that exists is promising","authors":"Alison Knopf","doi":"10.1002/cpu30861","DOIUrl":"https://doi.org/10.1002/cpu30861","url":null,"abstract":"","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140552077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pregnancy and high levels of opioids for pain don't mix","authors":"Alison Knopf","doi":"10.1002/cpu30863","DOIUrl":"https://doi.org/10.1002/cpu30863","url":null,"abstract":"","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140552076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In the first head-to-head study of nalmefene nasal spray (OPVEE is the trade name) vs. naloxone to reverse opioid overdose conducted in volunteers, researchers found that nalmefene worked faster than a 4 milligram (mg) dose of naloxone. It worked much faster, in fact, 2.7 mgs of OPVEE reversed respiratory depression within 5 minutes, compared to 20 minutes for 4 mgs of naloxone. The opioid that was given to the volunteers was remifentanil, a synthetic opioid.
{"title":"Nalmefene study: A faster alternative to naloxone","authors":"Alison Knopf","doi":"10.1002/cpu30857","DOIUrl":"https://doi.org/10.1002/cpu30857","url":null,"abstract":"<p>In the first head-to-head study of nalmefene nasal spray (OPVEE is the trade name) vs. naloxone to reverse opioid overdose conducted in volunteers, researchers found that nalmefene worked faster than a 4 milligram (mg) dose of naloxone. It worked much faster, in fact, 2.7 mgs of OPVEE reversed respiratory depression within 5 minutes, compared to 20 minutes for 4 mgs of naloxone. The opioid that was given to the volunteers was remifentanil, a synthetic opioid.</p>","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140552073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
About 11% of 12th graders have used delta-8 tetrahydrocannabinol (THC) in the past year, according to an analysis of last year's Monitoring the Future Study which is conducted by the National Institute on Drug Abuse (NIDA).
根据美国国家药物滥用研究所（NIDA）对去年 "监测未来研究"（Monitoring the Future Study）的分析，约有 11% 的十二年级学生在过去一年中使用过δ-8-四氢大麻酚（THC）。
{"title":"NIDA: More than 11% of high school seniors use delta-8, the unregulated THC","authors":"Alison Knopf","doi":"10.1002/cpu30858","DOIUrl":"https://doi.org/10.1002/cpu30858","url":null,"abstract":"<p>About 11% of 12th graders have used delta-8 tetrahydrocannabinol (THC) in the past year, according to an analysis of last year's Monitoring the Future Study which is conducted by the National Institute on Drug Abuse (NIDA).</p>","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140552074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Recent studies have found that women with autism spectrum disorder (ASD) have disparities in their treatment during pregnancy, resulting in adverse birth outcomes, according to background material introducing a study of a prospective birth cohort.
{"title":"Autistic traits in pregnancy linked to adverse birth outcomes","authors":"Alison Knopf","doi":"10.1002/cpu30859","DOIUrl":"https://doi.org/10.1002/cpu30859","url":null,"abstract":"<p>Recent studies have found that women with autism spectrum disorder (ASD) have disparities in their treatment during pregnancy, resulting in adverse birth outcomes, according to background material introducing a study of a prospective birth cohort.</p>","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140552802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Teens prescribed stimulants for ADHD not likely to have later drug misuse","authors":"Alison Knopf","doi":"10.1002/cpu30862","DOIUrl":"https://doi.org/10.1002/cpu30862","url":null,"abstract":"","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140552078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号